Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 6/20 | 0.68 |
| ▸ | CCR1 | P32246 | 2/20 | 0.68 |
| ▸ | CCR5 | P51681 | 2/20 | 0.68 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | CCR4 | P51679 | 1/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.55 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.54 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3148243 | 0.87 | CCR2 (0.70) | CCR2CCR1CCR5 | |
| SCHEMBL2897956 | 0.85 | CCR1 (0.60) | CCR2CCR1CCR5CYP1A2CYP2C9 | |
| SCHEMBL3148207 | 0.85 | CCR2 (0.55) | CCR2CCR1CCR5CYP2C9 | |
| SCHEMBL3050790 | 0.83 | PTPN1 (0.61) | CCR2CCR1CCR5 | |
| SCHEMBL3054749 | 0.82 | CCR1 (0.54) | CCR2CCR1CCR5PTGDR2 | |
| SCHEMBL3052654 | 0.82 | CCR2 (0.66) | CCR2CCR1CCR5CYP1A2CYP3A4 | |
| SCHEMBL13146531 | 0.82 | PGR (0.67) | CCR2CCR1CCR5CYP1A2CYP3A4 | |
| SCHEMBL3055014 | 0.81 | CCR2 (0.64) | CCR2CCR1CCR5CYP1A2CYP3A4 | |
| SCHEMBL3049201 | 0.80 | CCR2 (0.57) | CCR2CCR1CCR5CYP1A2CYP3A4 | |
| SCHEMBL7127133 | 0.80 | CCR2 (0.73) | CCR2CCR1CCR5CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2074083-B1 | NEW SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | RICHTER GEDEON NYRT (HU) | 2013-06-19 | — | — | EP | disclosed |
| US-20100075978-A1 | SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | RICHTER GEDEON NYRT. (HU) | 2010-03-25 | — | — | US | disclosed |
| EP-2074083-A1 | NEW SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | Richter Gedeon NYRT (HU) | 2009-07-01 | — | — | EP | disclosed |
| WO-2008050168-A1 | NEW SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | RICHTER GEDEON NYRT. (HU) | 2008-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075978-A1 | SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | BDKRB1, BDKRB2, TRPV1 | CCR2 417/4885CCR1 358/4885CCR5 584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.